Clinical trials: PSMA PET/CT
Prostate Cancer, PET/CT
68Ga-XACP3 PET/CT in Prostate Cancer
The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.
- Conditions
- Prostate Cancer, PET/CT, ACP3
- Trial name
- NCT07242014
- Testing
- Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Prostate Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
- Trial name
- NCT03471650
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HNSCC
Dose-Effect Relation of Salivary Gland Irradiation
Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently understood.
- Trial name
- NCT03367780
- Testing
- PSMA PET/CT-scan
- Where
- 3 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
In this study, the investigators intend to validate 18F-DCFPyL test-retest reproducibility in metastatic lesions, in order to investigate whether it serves as a reliable response assessment tool, both to interpret existing…
- Trial name
- NCT03793543
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer
Prostate cancer (PCa) is currently the most common cancer in men in Finland (www.cancerregistry.fi). Although prognosis is very good in majority of men, it is noteworthy that still up to 20% of PCa cases are metastatic at the…
- Trial name
- NCT06219746
- Testing
- PSMA-imaging
- Where
- Finland
- Volunteers
- 320 people
- Sponsor
- Turku University Hospital
Prostate Cancer
Radical Prostatectomy Without Prior Biopsy
This pilot comparative study will evaluate a one-stage diagnostic and surgical strategy for patients with a high probability of clinically significant prostate cancer who have not undergone a separate preoperative prostate…
- Trial name
- NCT07819760
- Testing
- Transperineal Fusion-Targeted Prostate Biopsy With Intraoperative Frozen Section Examination, Robot-Assisted Radical Prostatectomy With Pelvic Lymph Node Dissection, Standard Transperineal Fusion Prostate Biopsy
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Botkin Hospital
Renal Cell Carcinoma
Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
Renal Cell Carcinoma (RCC) is the second most common tumor in urology. Considering its origination from kidney, an organ with intense physiological uptake and excretion of 68Ga-PSMA, this study aims to evaluate the uptake of…
- Trial name
- NCT05170555
- Testing
- 68Ga-PSMA, 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer
Ga-68 PSMA PET/CT vs mpMRI in Cognitive Prostate Biopsy
Prostate cancer is the most common malignancy among elderly men. With the routine use of prostate-specific antigen (PSA) testing since the 1980s, the incidence of prostate cancer has significantly increased.
- Trial name
- PSMA-MRI BX (NCT07533344)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer.
- Trial name
- PRIDE2-PC (NCT07568613)
- Testing
- MRI, 18F-PSMA1007 PET-CT, MR-guided TRUS Prostate biopsy
- Where
- Cyprus
- Volunteers
- 50 people
- Sponsor
- German Oncology Center, Cyprus
PSMA PET/CT, Prostate Cancer
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy
- Conditions
- PSMA PET/CT, Prostate Cancer, MpMRI
- Trial name
- NCT06901492
- Testing
- Prostate biopsy guided by PSMA PET/CT, Prostate biopsy guided by mpMRI/US, Systematic prostate biopsy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Prostate Neoplasms
Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer
The purpose of this study is to assess the detection rate of local relapse after radical prostatectomy with either PSMA or 64Cu-PET/CTs and whether the delineation of relapsed lesions using both methods can facilitate/change the…
- Trial name
- NCT04703543
- Testing
- Pilot evaluation study on use PSMA and Cu-PET/CT
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic…
- Trial name
- NCT03800784
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent)…
- Trial name
- NCT02940262
- Testing
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 1,138 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Broadly, the objective of this study is to evaluate the fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer following treatment with radium-223 as a…
- Trial name
- NCT03062254
- Testing
- radium-223 dichloride
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic